Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats - PubMed (original) (raw)
Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats
H Vlassara et al. Proc Natl Acad Sci U S A. 1994.
Abstract
High levels of tissue advanced glycation end products (AGEs) that result from the spontaneous modification of proteins by glucose occur in diabetes and aging. To address the potential pathogenic role of AGEs in the glomerulosclerosis of diabetes or nephrosclerosis of aging, doses of AGE-modified rat albumin (25 mg per kg per day, i.v.) sufficient to elevate circulating AGE levels to the range of diabetic serum were administered daily to healthy rats alone or in combination with the AGE inhibitor aminoguanidine. After 5 months, the AGE content of renal tissues in AGE-treated rats rose to 50% above controls (P < 0.025), whereas serum contained 2.8-fold greater AGE levels (P < 0.025). Light and electron microscopy of kidneys from AGE-treated rats revealed a more than 50% increase in glomerular volume compared to controls (P < 0.001), significant periodic acid/Schiff reagent-positive deposits, basement membrane widening, and mesangial extracellular matrix increase and indicated significant glomerulosclerosis compared to untreated (P < 0.002) or albumin-treated controls (P < 0.002). These changes were associated with significant loss of protein (P < 0.005) and albumin (P < 0.002) in the urine of AGE-treated rats compared to controls. Cotreatment with aminoguanidine markedly limited both the structural and functional defects. These in vivo data demonstrate that AGEs influence glomerular structure and function in a manner leading to glomerulosclerosis. The effects are AGE-specific, as they are ameliorated by a pharmacological AGE inhibitor, aminoguanidine.
Similar articles
- Effects of aminoguanidine on serum advanced glycation endproducts, urinary albilmin excretion, mesangial expansion, and glomerular basement membrane thickening in Otsuka Long-Evans Tokushima fatty rats.
Yamauchi A, Takei I, Makita Z, Nakamoto S, Ohashi N, Kiguchi H, Ishii T, Koike T, Saruta T. Yamauchi A, et al. Diabetes Res Clin Pract. 1997 Jan;34(3):127-33. doi: 10.1016/s0168-8227(96)01339-3. Diabetes Res Clin Pract. 1997. PMID: 9069563 - Aminoguanidine inhibits albuminuria, but not the formation of advanced glycation end-products in skin collagen of diabetic rats.
Degenhardt TP, Fu MX, Voss E, Reiff K, Neidlein R, Strein K, Thorpe SR, Baynes JW, Reiter R. Degenhardt TP, et al. Diabetes Res Clin Pract. 1999 Feb;43(2):81-9. doi: 10.1016/s0168-8227(98)00121-1. Diabetes Res Clin Pract. 1999. PMID: 10221660 - Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications.
Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R. Vlassara H, et al. Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12043-7. doi: 10.1073/pnas.89.24.12043. Proc Natl Acad Sci U S A. 1992. PMID: 1465438 Free PMC article. - Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine.
Li YM, Steffes M, Donnelly T, Liu C, Fuh H, Basgen J, Bucala R, Vlassara H. Li YM, et al. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3902-7. doi: 10.1073/pnas.93.9.3902. Proc Natl Acad Sci U S A. 1996. PMID: 8632987 Free PMC article. - Advanced glycation end-products and atherosclerosis.
Vlassara H. Vlassara H. Ann Med. 1996 Oct;28(5):419-26. doi: 10.3109/07853899608999102. Ann Med. 1996. PMID: 8949973 Review.
Cited by
- An overview on glycation: molecular mechanisms, impact on proteins, pathogenesis, and inhibition.
Uceda AB, Mariño L, Casasnovas R, Adrover M. Uceda AB, et al. Biophys Rev. 2024 Apr 12;16(2):189-218. doi: 10.1007/s12551-024-01188-4. eCollection 2024 Apr. Biophys Rev. 2024. PMID: 38737201 Free PMC article. Review. - Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression.
Wang N, Zhang C. Wang N, et al. Int J Mol Sci. 2024 Mar 7;25(6):3086. doi: 10.3390/ijms25063086. Int J Mol Sci. 2024. PMID: 38542060 Free PMC article. Review. - Ultraprocessed foods and chronic kidney disease-double trouble.
Avesani CM, Cuppari L, Nerbass FB, Lindholm B, Stenvinkel P. Avesani CM, et al. Clin Kidney J. 2023 May 4;16(11):1723-1736. doi: 10.1093/ckj/sfad103. eCollection 2023 Nov. Clin Kidney J. 2023. PMID: 37915903 Free PMC article. Review. - The AGE-RAGE Axis and the Pathophysiology of Multimorbidity in COPD.
Reynaert NL, Vanfleteren LEGW, Perkins TN. Reynaert NL, et al. J Clin Med. 2023 May 9;12(10):3366. doi: 10.3390/jcm12103366. J Clin Med. 2023. PMID: 37240472 Free PMC article. Review. - Resveratrol Alleviates Advanced Glycation End-Products-Related Renal Dysfunction in D-Galactose-Induced Aging Mice.
Lan KC, Peng PJ, Chang TY, Liu SH. Lan KC, et al. Metabolites. 2023 May 13;13(5):655. doi: 10.3390/metabo13050655. Metabolites. 2023. PMID: 37233696 Free PMC article.
References
- Lancet. 1994 Jun 18;343(8912):1519-22 - PubMed
- Lab Invest. 1994 Feb;70(2):138-51 - PubMed
- Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9441-5 - PubMed
- Clin Chim Acta. 1980 Jun 10;104(2):161-7 - PubMed
- Clin Exp Immunol. 1985 Feb;59(2):293-9 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources